Sentinel node biopsy for primary cutaneous melanoma
- PMID: 33484834
- DOI: 10.1016/j.annonc.2021.01.007
Sentinel node biopsy for primary cutaneous melanoma
Conflict of interest statement
Disclosure JEG—outside current work—consultant and/or advisory boards: Merck, Novartis, Bristol-Myers Squibb, Regeneron, Syndax; MBF—outside current work—advisory boards: Novartis, Merck, Bristol-Myers Squibb, Pulse Biosciences, Sanofi, Nektar; AT has declared no conflicts of interest.
Comment on
-
Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor.Ann Oncol. 2021 Mar;32(3):375-383. doi: 10.1016/j.annonc.2020.11.015. Epub 2020 Nov 28. Ann Oncol. 2021. PMID: 33253862
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical